ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2203

Atherosclerotic Inflammation in Rheumatoid Arthritis Patients: A Post-Hoc Study Using Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography

Yukio Yonemoto1, Masahiro Tachibana2, Koichi OKAMURA1, Takahito SUTO1, Hideo SAKANE1, Chisa OKURA1, Tetsuya Kaneko2 and Hirotaka CHIKUDA1, 1Orthopaedic Surgery, Gunma University Graduate School of Medicine, MAEBASHI, Japan, 2Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: 18FDG PET/CT scan, arteriosclerosis and rheumatoid arthritis (RA), Biologics

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Imaging of Rheumatic Diseases Poster III: Other Modalities

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) has long been associated with an increased cardiovascular risk, and despite substantial improvements in disease management, its associated mortality remains high. Several reports have suggested that treatment with TNF inhibitors might have a beneficial effect on the cardiovascular risk. However, few studies have quantitatively investigated the relationship between RA and atherosclerotic inflammation. [18F] fluorodeoxyglucose-positron emission tomography (FDG-PET) has been used to assess synovitis in patients with RA and to evaluate the disease activity of RA. In addition, the FDG accumulation has been reported to indicate atherosclerotic inflammation. The aim of this study was to evaluate the relationship between atherosclerotic inflammation and biologics using FDG-PET.

Methods: Sixty RA patients (14 males, 46 females, average age 58.3 [range 17-80] years) treated with biological therapies were assessed. FDG-PET was performed at baseline and six months after the initiation of biological therapy. The carotid FDG uptake was measured by obtaining the standardized uptake values from the carotid of each patient, and the ratio of the carotid to background (blood) activity was determined (TBR). We also evaluated the Disease Activity Score 28 C-reactive protein (DAS28-CRP) and several clinical parameters (CRP, erythrocyte sedimentation rate [ESR], anti-cyclic citrullinated peptide antibody [ACPA], rheumatoid factor [RF], matrix metalloproteinase 3 [MMP-3]). Student’s t-test, chi-square test and logistic regression analysis were used to assess the factors influencing the decrease in the TBR.

Results: At six months after starting biological therapies, the values for DAS28-CRP, CRP, ESR, and MMP-3 were significantly decreased. However, the carotid TBR was not significantly improved (1.17 to 1.18). The ACPA and RF values also did not change markedly after treatment. The age, change in the white blood cell count, and carotid TBR at baseline were lower in the decrease TBR group than in increase TBR group. In the logistic regression group, a young age and a low carotid TBR at baseline were factors influencing the decrease in the carotid TBR.

Conclusion: In this study, a young age and a low carotid TBR at baseline were factors influencing the decrease in the carotid TBR. These results suggest that biologics improve not only the disease activity but also atherosclerotic inflammation, especially in young RA patients.


Disclosure: Y. Yonemoto, None; M. Tachibana, None; K. OKAMURA, None; T. SUTO, None; H. SAKANE, None; C. OKURA, None; T. Kaneko, None; H. CHIKUDA, None.

To cite this abstract in AMA style:

Yonemoto Y, Tachibana M, OKAMURA K, SUTO T, SAKANE H, OKURA C, Kaneko T, CHIKUDA H. Atherosclerotic Inflammation in Rheumatoid Arthritis Patients: A Post-Hoc Study Using Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/atherosclerotic-inflammation-in-rheumatoid-arthritis-patients-a-post-hoc-study-using-fluorodeoxyglucose-positron-emission-tomography-computed-tomography/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/atherosclerotic-inflammation-in-rheumatoid-arthritis-patients-a-post-hoc-study-using-fluorodeoxyglucose-positron-emission-tomography-computed-tomography/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology